Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Noninvasive molecular imaging of neuroinflammation.
Conference Report: Multiple Sclerosis Update: Hot topics from 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS).
Neuropsychological Aspects of Childhood Multiple Sclerosis: An Overview.
Bag3-Induced Autophagy Is Associated with Degradation of JCV Oncoprotein, T-Ag.
Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection.
Phase 2 results of the RADIANCE trial: a randomized, double-blind, placebo-controlled trial of oral RPC1063 in relapsing multiple sclerosis
A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosis.
Kappa free light chains: diagnostic and prognostic relevance in MS and CIS.
Epidermal pigmentation in the human lineage is an adaptation to ultraviolet radiation.
Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
Do positive or negative stressful events predict the development of new brain lesions in people with multiple sclerosis?
Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells.
Cerebrospinal fluid anti-whole myelin antibodies are not correlated to magnetic resonance imaging activity in multiple sclerosis.
A safety and pharmacokinetic study of intravenous natalizumab in patients with MS.
The Arabic version of the Mayo-Portland Adaptability Inventory 4: a validation study.
Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis.
Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis.
Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis.
Association between Change in Normal Appearing White Matter Metabolites and Intrathecal Inflammation in Natalizumab-Treated Multiple Sclerosis.
New TYSABRI® data show earlier treatment and longer-term use result in significant reductions in MS disease activity
A molecular link between the active component of marijuana and Alzheimer's disease pathology.
New data at AAN to confirm efficacy of Novartis' Gilenya® across four key measures of MS disease activity, including brain volume loss
Neuroprotective effects of riluzole in neurotrauma models: a review.
Comorbid Multiple Sclerosis and TDP-43 Proteinopathy in a Gulf War Sea Captain.
The Safety Profile of Dalfampridine Extended Release in Multiple Sclerosis Clinical Trials.

Pages